EMA To Draw Up 'Critical Medicine' Lists For Future Health Crises
Industry Will Be ‘Invited’ To Review Product Lists
As part of its expanded mandate, the EU regulator is identifying those medicines whose supply will need to be closely monitored during health crisis situations. The lists will draw on various information sources, including real-world evidence databases.
You may also be interested in...
Coronavirus Notebook: Global COVID-19 Summit To Press For More Funding For Vaccines & Treatments, WHO Calls For End To IP Waiver ‘Stalemate’
CEPI has announced funding for a “variant-proof” vaccine being developed by a multidisciplinary consortium. The European Medicines Agency's new committee on drug shortages in health crises has held its first meeting, and the European Parliament’s new COVID-19 committee will quiz the health commissioner on the EU’s vaccines strategy and response to the pandemic.
The proposed European Health Data Space is expected to boost innovation in preventing, diagnosing and treating disease and to support the long-term competitiveness of the EU’s medical sector. The pharmaceutical industry has broadly welcomed the move but wants to see certain safeguards and guarantees put in place.
Drug approvals, clinical trials, pharmacovigilance and the use of unauthorized drugs are among areas targeted by draft legislation on a new therapeutic products scheme.